Dashboard
1
The company has declared positive results in Dec'2024 after 4 consecutive negative quarters
- PRE-TAX PROFIT(Q) At SEK 3.53 MM has Grown at 1,264.8%
- NET PROFIT(Q) At SEK 2.13 MM has Grown at 614.91%
- ROCE(HY) Highest at 4.9%
2
With ROE of 4.85%, it has a fair valuation with a 1.35 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
SEK 135 Million (Micro Cap)
28.00
NA
0.00%
0.26
7.89%
1.32
Revenue and Profits:
Net Sales:
143 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.52%
0%
-2.52%
6 Months
4.04%
0%
4.04%
1 Year
48.72%
0%
48.72%
2 Years
36.47%
0%
36.47%
3 Years
-21.62%
0%
-21.62%
4 Years
-72.38%
0%
-72.38%
5 Years
-59.15%
0%
-59.15%
New Nordic Healthbrands AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.19%
EBIT Growth (5y)
-14.06%
EBIT to Interest (avg)
6.62
Debt to EBITDA (avg)
1.79
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
3.80
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.82%
ROE (avg)
5.79%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.35
EV to EBIT
16.67
EV to EBITDA
13.01
EV to Capital Employed
1.27
EV to Sales
0.29
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
7.63%
ROE (Latest)
4.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
143.00
143.80
-0.56%
Operating Profit (PBDIT) excl Other Income
4.40
5.50
-20.00%
Interest
0.30
1.10
-72.73%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.10
2.70
-22.22%
Operating Profit Margin (Excl OI)
26.40%
34.10%
-0.77%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -0.56% vs -3.88% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -22.22% vs 42.11% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
550.30
533.80
3.09%
Operating Profit (PBDIT) excl Other Income
-2.80
-1.90
-47.37%
Interest
2.70
2.60
3.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.70
-6.20
-24.19%
Operating Profit Margin (Excl OI)
-8.10%
-5.90%
-0.22%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.09% vs 9.50% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -24.19% vs -121.43% in Dec 2023
About New Nordic Healthbrands AB 
New Nordic Healthbrands AB
Pharmaceuticals & Biotechnology
New Nordic Healthbrands AB (New Nordic) is a Sweden-based food supplement and naturopathy company. The Company develops and sells dietary supplements, herbal remedies and related personal care products. New Nordic offers products in such segments as Diet, which includes brand names Apple Cider, BioFirm and Chili Burn, among others; Vitality, which includes brands Blue Berry, Frutin, Active Liver and dida, among others, and Beauty, which includes product lines Hair Volume, Nail Strong and Skin Care, among others. New Nordic's products are available in more than 30 countries, with focus on the Nordic region and the United States.
Company Coordinates 
Company Details
Sodra Forstadsgatan 3 , MALMO None : 21143
Registrar Details






